Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant
  1. Alan Martin Edwards1,
  2. Štěpánka Čapková2
  1. 1The David Hide Asthma and Allergy Research Centre, St Mary’s Hospital, Newport, Isle Of Wight, UK
  2. 2Department of Pediatric Dermatology, FN Motol, University Hospital, Prague, Czech Republic
  1. Correspondence to Dr Alan Martin Edwards, dramedwards{at}


Diffuse cutaneous mastocytosis (DCM) is a rare, severe, variant of cutaneous mastocytosis. The authors report the case of a male infant who developed maculae and maculopapulae on his legs and abdomen when aged 3.5 months, which spread to all body surfaces within weeks. Diagnosis of DCM was made at the age of 6 months when he had developed extensive bullous eruptions, generalised pruritus, flushing and abdominal pain. Treatment was started with oral dimethindine maleate. At the age of 18 months, oral sodium cromoglicate (SCG) was introduced. At the age of 23 months, additional treatment was started with a cutaneous emulsion containing 4% SCG. Continued treatment with oral dimethindine maleate, oral SCG with the dose maintained at 25 mg/kg/day, and SCG 4% cutaneous emulsion applied two to four times daily has resulted in a steady improvement of symptoms and skin appearance.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests AME was employed by the originators of sodium cromoglicate, Fisons Pharmaceuticals from 1974 to 1995. He is a consultant to the manufacturers of Altoderm, a 4% cutaneous emulsion of sodium cromoglicate, Thornton & Ross. ŠČ has no competing interest.

  • Patient consent Obtained.